re: Ann: CAVATAK anti-cancer activity - US Ca...
Yes 60% and that's slightly better than the Biovex results.
Reading the CEO presentation is eye opening. Looking at the trial results, they're outstanding and IMO put VLA in the same league, or better than, PBT, AHZ, and similar.
Look at the photos of the skin tumours before and after treatment.
Check out the credentials of the scientific advisors and in particular Dr Antabacka who is presenting these results to the upcoming American Cancer Conference.
And of course now funded to 2016.
And yet the SP is still bouncing along the bottom.
I hold ADO, AHZ, NEU and others and I regularly look for other bio techs. I honestly can't find one with the potential of VLA. It's a shame I couldn't participate in the spp as I now live in UK but I am strongly considering selling down some of my others for this baby.
VLA Price at posting:
31.5¢ Sentiment: LT Buy Disclosure: Held
